Medicines labeled for the same conditions
Alternatives to datopotamab deruxtecan
20 other medicines are given the same way (intravenous) and in the same FDA class as datopotamab deruxtecan or labeled mainly for the same use (lung cancer); the others include 3 programmed death receptor-1 blocking antibodies, 2 microtubule inhibitors and 2 topoisomerase inhibitors (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as datopotamab deruxtecan?
Lung cancer lists all 55 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Datopotamab deruxtecan | this medicine | none listed | n/a | No | No current entry |
| Pemetrexedfolate analog metabolic inhibitor | Lung cancer | 15 labelers | n/a | No | A presentation being discontinued |
| Docetaxelmicrotubule inhibitor | Breast cancer, Lung cancer | 14 labelers | n/a | Yes | A presentation being discontinued |
| Paclitaxelmicrotubule inhibitor | Breast cancer, Lung cancer | 20 labelers | n/a | Yes | No current entry |
| Gemcitabinenucleoside metabolic inhibitor | Breast cancer, Lung cancer | 10 labelers | n/a | No | No current entry |
| Etoposidetopoisomerase inhibitor | Lung cancer | 5 labelers | n/a | Yes | No current entry |
| Topotecantopoisomerase inhibitor | Lung cancer | 4 labelers | n/a | Yes | No current entry |
| Nivolumabprogrammed death receptor-1 blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Atezolizumabprogrammed death receptor-1 blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Durvalumabprogrammed death ligand-1 blocker | Lung cancer | none listed | n/a | No | No current entry |
| Ipilimumabctla-4-directed blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Ramucirumabvascular endothelial growth factor receptor 2 antagonist | Lung cancer | none listed | n/a | No | No current entry |
| Telisotuzumab vedotin | Lung cancer | none listed | n/a | No | No current entry |
| Tremelimumabctla-4-directed blocking antibody | Lung cancer | none listed | n/a | No | No current entry |
| Vinorelbinevinca alkaloid | Lung cancer | 2 labelers | n/a | Yes | No current entry |
| Zenocutuzumab | Lung cancer | none listed | n/a | Yes | No current entry |
| Pembrolizumabprogrammed death receptor-1 blocking antibody | Breast cancer, Lung cancer | none listed | n/a | No | No current entry |
| Trastuzumab deruxtecan | Breast cancer, Lung cancer | none listed | n/a | Yes | No current entry |
| Amivantamab | Lung cancer | none listed | n/a | No | No current entry |
| Cemiplimab | Lung cancer | none listed | n/a | No | No current entry |
| Lurbinectedinalkylating drug | Lung cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Datopotamab deruxtecan: the full record
- label, generics, price, shortages, recalls